Navigation Links
Biopure Receives Notice of Nasdaq Delisting
Date:6/30/2009

CAMBRIDGE, Mass., June 30 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced that it has received notice from The Nasdaq Stock Market, by letter dated June 24, 2009, that it is out of compliance with the Nasdaq Marketplace Rules and its common stock may be delisted. The notice stated that the company no longer meets the minimum of $2,500,000 in stockholders' equity for continued listing on the Nasdaq Capital Market.

Nasdaq advised that the company has 15 calendar days to submit a plan to regain compliance. If such plan is accepted, Nasdaq may grant an extension of up to 105 days from the date of notification to regain compliance. If the Company is unable to regain compliance its common stock will be delisted. The company does not intend to submit a plan to regain compliance.

Biopure Corporation

Biopure Corporation develops and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. The company has limited remaining cash. It is exploring the potential sale of some, substantially all, or all of its assets, and is evaluating liquidation.

    Contact:  Zaf Zafirelis
              Biopure Corporation
              (617) 234-6500
              IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Biopure Announces Reverse Stock Split
2. Biopures Stock Symbol Reverts to BPUR
3. Biopure Announces Closing of $14.9 Million Financing
4. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
5. Biopure Announces 2007 Fourth Quarter and Year-End Financial Results
6. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
7. Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
8. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
9. Agency Takes Adverse Decision to Biopures Product Registration in South Africa
10. Biopure Sues National Institutes of Health Official
11. Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 2017 , ... Tribble Insurance Agency, a family owned and operated firm offering ... charity event to honor Chad Phillip Dermyer, a local police trooper who was shot ... and his fellow officers were conducting routine stops of suspects when one of them, ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the second consecutive year, ... Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. Spencer Richlin, ... been chosen by their peers for the 2017 list based on their exceptional ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based sales ... market. , Over the past 20 years SFI has been recognized as the world’s ... six new clients into the US market. The new clients include: Panacea Pro, ...
(Date:1/19/2017)... ... January 19, 2017 , ... Fillers are known ... Few people know that popular cosmetic fillers can enhance earlobes and ... medical director of the MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of Bioengineering are collaborating on a research project focused on multiple sclerosis (MS). ... seeks to use nanotechnology to control the disease without compromising normal immune function ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 ... administration appears serious about reducing the FDA,s regulatory ... innovation in the medical drug industry, many of ... with new clinical trials and development of advanced ... forging ahead with recent developments include:  Moleculin Biotech, ...
(Date:1/19/2017)... 2017  Magnetic Insight Inc., leader in magnetic ... agreement with inviCRO LLC to develop intuitive image ... based on inviCRO,s VivoQuant™ visualization and post processing ... complete MPI solution package with the Momentum MPI ... imaging in vivo. MPI is a ...
(Date:1/18/2017)... 18, 2017  EnteroMedics Inc. (NASDAQ: ... neuroblocking technology to treat obesity, metabolic diseases and ... an underwritten public offering of units for gross ... discounts and commissions and offering expenses payable by ... Class A Units, priced at a public offering ...
Breaking Medicine Technology: